{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:17:58Z","timestamp":1789013878203,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12185-022-03430-9","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T20:02:46Z","timestamp":1660161766000},"page":"947-955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Anakinra for the treatment of adult secondary HLH: a retrospective experience"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-1307","authenticated-orcid":false,"given":"Leonard","family":"Naymagon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"3430_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/asheducation-2013.1.605","volume":"2013","author":"GE Janka","year":"2013","unstructured":"Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematol Am Soc Hematol Educ Program. 2013;2013:605\u201311.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3430_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153321","volume":"218","author":"L Naymagon","year":"2021","unstructured":"Naymagon L. Can we truly diagnose adult secondary hemophagocytic lymphohistiocytosis (HLH)? A critical review of current paradigms. Pathol Res Pract. 2021;218: 153321.","journal-title":"Pathol Res Pract"},{"issue":"7","key":"3430_CR3","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367\u201373.","journal-title":"Blood"},{"issue":"5","key":"3430_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1159\/000514920","volume":"144","author":"L Naymagon","year":"2021","unstructured":"Naymagon L, Tremblay D, Mascarenhas J. The efficacy of etoposide-based therapy in adult secondary hemophagocytic lymphohistiocytosis. Acta Haematol. 2021;144(5):560\u20138.","journal-title":"Acta Haematol"},{"issue":"10","key":"3430_CR5","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.clml.2018.06.014","volume":"18","author":"E Apodaca","year":"2018","unstructured":"Apodaca E, Rodriguez-Rodriguez S, Tuna-Aguilar EJ, Demichelis-Gomez R. Prognostic factors and outcomes in adults with secondary hemophagocytic lymphohistiocytosis: a single-center experience. Clin Lymphoma Myeloma Leuk. 2018;18(10):e373\u201380.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"3430_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","volume":"89","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484\u201392.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"3430_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjh.13837","volume":"172","author":"AM Schram","year":"2016","unstructured":"Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016;172(3):412\u20139.","journal-title":"Br J Haematol"},{"issue":"2","key":"3430_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1182\/blood.2019001333","volume":"134","author":"MS Zinter","year":"2019","unstructured":"Zinter MS, Hermiston ML. Calming the storm in HLH. Blood. 2019;134(2):103\u20134.","journal-title":"Blood"},{"issue":"1","key":"3430_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12969-019-0309-6","volume":"17","author":"O Halyabar","year":"2019","unstructured":"Halyabar O, Chang MH, Schoettler ML, Schwartz MA, Baris EH, Benson LA, et al. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019;17(1):7.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"9","key":"3430_CR10","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"51","key":"3430_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002318","volume":"94","author":"T Barba","year":"2015","unstructured":"Barba T, Maucort-Boulch D, Iwaz J, Bohe J, Ninet J, Hot A, et al. Hemophagocytic lymphohistiocytosis in intensive care unit: a 71-case strobe-compliant retrospective study. Medicine (Baltimore). 2015;94(51): e2318.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3430_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bjh.13102","volume":"168","author":"M Arca","year":"2015","unstructured":"Arca M, Fardet L, Galicier L, Riviere S, Marzac C, Aumont C, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol. 2015;168(1):63\u20138.","journal-title":"Br J Haematol"},{"issue":"7","key":"3430_CR13","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1080\/10428194.2020.1737684","volume":"61","author":"RJ Bubik","year":"2020","unstructured":"Bubik RJ, Barth DM, Hook C, Wolf RC, Muth JM, Mara K, et al. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leuk Lymphoma. 2020;61(7):1592\u2013600.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3430_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PCC.0000000000000078","volume":"15","author":"S Rajasekaran","year":"2014","unstructured":"Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med. 2014;15(5):401\u20138.","journal-title":"Pediatr Crit Care Med"},{"issue":"2","key":"3430_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3430_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","volume":"19","author":"O Phadke","year":"2021","unstructured":"Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S. Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. 2021;19(1):98.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"3430_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2011","unstructured":"Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50(2):417\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3430_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s10875-017-0439-x","volume":"37","author":"B Kumar","year":"2017","unstructured":"Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults. J Clin Immunol. 2017;37(7):638\u201343.","journal-title":"J Clin Immunol"},{"issue":"5","key":"3430_CR19","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/acr2.11135","volume":"2","author":"LA Monteagudo","year":"2020","unstructured":"Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. 2020;2(5):276\u201382.","journal-title":"ACR Open Rheumatol"},{"issue":"Supplement_2","key":"3430_CR20","doi-asserted-by":"publisher","first-page":"keaa109","DOI":"10.1093\/rheumatology\/keaa109.017","volume":"59","author":"L Sammut","year":"2020","unstructured":"Sammut L, Murryam S, Vincent N, Davidson B, Edwards CJ. EP18 use of anakinra for haemophagocytic lymphohistiocytosis in adults. Rheumatology. 2020;59(Supplement_2):keaa109\u201317.","journal-title":"Rheumatology"},{"issue":"9","key":"3430_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/0885066617711386","volume":"34","author":"P Wohlfarth","year":"2019","unstructured":"Wohlfarth P, Agis H, Gualdoni GA, Weber J, Staudinger T, Schellongowski P, et al. Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis. J Intensive Care Med. 2019;34(9):723\u201331.","journal-title":"J Intensive Care Med"},{"issue":"1","key":"3430_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","volume":"28","author":"G Dimopoulos","year":"2020","unstructured":"Dimopoulos G, de Mast Q, Markou N, Theodorakopoulou M, Komnos A, Mouktaroudi M, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020;28(1):117-123.e1.","journal-title":"Cell Host Microbe"},{"issue":"12","key":"3430_CR23","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2665-9913(20)30361-1","volume":"2","author":"A Kavirayani","year":"2020","unstructured":"Kavirayani A, Charlesworth JEG, Segal S, Kelly D, Wilson S, Qureshi A, et al. The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH. Lancet Rheumatol. 2020;2(12):e736\u20138.","journal-title":"Lancet Rheumatol"},{"key":"3430_CR24","volume-title":"Etoposide","author":"G Reyhanoglu","year":"2022","unstructured":"Reyhanoglu G, Tadi P. Etoposide. Treasure Island: In: StatPearls; 2022."},{"issue":"6 Suppl 13","key":"3430_CR25","first-page":"78","volume":"19","author":"K Kobayashi","year":"1992","unstructured":"Kobayashi K, Ratain MJ. New perspectives on the toxicity of etoposide. Semin Oncol. 1992;19(6 Suppl 13):78\u201383.","journal-title":"Semin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03430-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03430-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03430-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:29:33Z","timestamp":1744201773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03430-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3430"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03430-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"14 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author has no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}